| Machado-Joseph deubiquitinases: from cellular functions to potential therapy targets C Zeng, C Zhao, F Ge, Y Li, J Cao, M Ying, J Lu, Q He, B Yang, X Dai, ... Frontiers in Pharmacology 11, 1311, 2020 | 28 | 2020 |
| Deubiquitinating enzymes: Promising targets for drug resistance F Ge, Y Li, T Yuan, Y Wu, Q He, B Yang, H Zhu Drug Discovery Today 27 (9), 2603-2613, 2022 | 24 | 2022 |
| Akr1c1 connects autophagy and oxidative stress by interacting with sqstm1 in a catalytic-independent manner L Chang, Y Li, C Zhao, C Zeng, F Ge, J Du, W Zhang, P Lu, Q He, H Zhu, ... Acta Pharmacologica Sinica 43 (3), 703-711, 2022 | 10 | 2022 |
| The calcimimetic agent cinacalcet inhibits hepatocellular carcinoma via YAP/TAZ suppression L Zheng, J Du, F Ge, M Qian, B Yang, Q He, Q Weng, H Zhu Die Pharmazie-An International Journal of Pharmaceutical Sciences 76 (10 …, 2021 | 5 | 2021 |
| Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting LKB1 (Liver kinase B1) activity T Yuan, C Zeng, J Liu, C Zhao, F Ge, Y Li, M Qian, J Du, W Wang, Y Li, ... Signal Transduction and Targeted Therapy 9 (1), 11, 2024 | 4 | 2024 |
| Cancer-associated fibroblasts drive early pancreatic cancer cell invasion via the SOX4/MMP11 signalling axis F Ge, C Zeng, J Wang, X Liu, C Zheng, H Zhang, L Yang, B Yang, H Zhu, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1870 (1), 166852, 2024 | 4 | 2024 |
| The molecular mechanisms and targeting strategies of transcription factors in cholangiocarcinoma J Wang, F Ge, T Yuan, M Qian, F Yan, B Yang, Q He, H Zhu Expert Opinion on Therapeutic Targets 26 (9), 781-789, 2022 | 2 | 2022 |
| Glycyrrhizic acid: a potential drug against COVID-19 F GE, C ZENG, F YAN, M QIAN, W WANG, P LUO, Q WENG, R ZHUANG, ... Acta Pharmaceutica Sinica, 1211-1216, 2021 | 2 | 2021 |
| Ivacaftor, a CFTR potentiator, synergizes with osimertinib against acquired resistance to osimertinib in NSCLC by regulating CFTR-PTEN-AKT axis Y Li, F Ge, X Liu, C Zeng, M Qian, Y Li, M Zheng, J Qu, L Fang, J Lu, ... Acta Pharmacologica Sinica, 1-13, 2024 | 1 | 2024 |
| The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells. X Dai, X Liu, F Ge, H Zhu, C Zheng, F Yan, B Yang Zhejiang da xue xue bao. Yi xue ban= Journal of Zhejiang University. Medical …, 2023 | 1 | 2023 |
| Deubiquitinating enzyme JOSD2 affects susceptibility of non-small cell lung carcinoma cells to anti-cancer drugs through DNA damage repair. F Ge, X Liu, H Zhang, T Yuan, H Zhu, B Yang, Q He Zhejiang da xue xue bao. Yi xue ban= Journal of Zhejiang University. Medical …, 2023 | 1 | 2023 |
| JOSD2 promotes breast cancer metastasis by deubiquitinating and stabilizing SMAD4 J Du, J Wang, F Ge, H Ma, H Zhu, J Du, F Yan, Q He, B Yang, T Yuan, ... Biochemical Pharmacology 232, 116748, 2025 | | 2025 |
| Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient F Ge, X Dai, Y Qiu, X Liu, C Zeng, X Xu, Y Chen, H Zhu, Q He, R Gai, ... Acta Pharmacologica Sinica, 1-12, 2024 | | 2024 |
| Deubiquitinating enzyme JOSD2 affects susceptibility of NSCLC cells to anti-cancer drugs through DNA damage repair. F Ge, X Liu, H Zhang, T Yuan, H Zhu, B Yang, Q He Zhejiang da xue xue bao. Yi xue ban= Journal of Zhejiang University. Medical …, 2023 | | 2023 |